title: Liver transplantation in HIV-infected recipients.
abstract: Liver transplantation is being evaluated as a therapeutic option for human immunodeficiency virus (HIV)-infected patients with end-stage liver disease, but experience is still scarce. We describe the outcome of 4 HIV-infected patients who underwent liver transplantation in our hospital between July 2002 and April 2003. HIV-infected liver transplant recipients meet the same standard criteria for transplantation as do HIV-negative candidates. In addition, HIV infected persons are required to have a CD4 T-cell count greater than 100/mL (CD4 T-cells are targets for HIV infection). Immunosuppressive regimens, perioperative surgical prophylaxis, and prophylaxis for opportunistic infections are standard in the Liver Transplantation Unit in our hospital. Four patients, including 3 former intravenous drug users, received a liver transplant (2 from deceased donors and 2 from living donors), with a median follow-up of 510 days. Three patients (75%) are alive, with 1 death occurring 17 months posttransplantation in a patient who developed fibrosing cholestatic hepatitis. Rejection occurred in 1 patient, and was managed with no complications. Hepatitis C virus (HCV) recurrence occurred in 3 patients. HIV-infection has remained under control with antiretroviral treatment. A combination of 3 nucleoside analogs was used in 3 patients, with no need for drug adjustments. No opportunistic infections or other significant infectious complications developed. In conclusion, orthotopic liver transplantation seems a safe therapeutic option in the short term for HIV-infected persons with end stage liver disease, including patients with a history of drug abuse. If indicated, an antiretroviral regimen consisting of 3 nucleosides could be used to avoid interactions with immunosuppressive drugs.
authors.affiliation: Department of Infectious Diseases, Liver Transplant Unit, Hospital Ramón y Cajal, Universidad de Alcalá de Henares, 28034 Madrid, Spain. smoreno.hrc@salud.madrid.org
authors.forename: Santiago
authors.initials: S
authors.lastname: Moreno
authors.forename: Jesús
authors.initials: J
authors.lastname: Fortún
authors.forename: Carmen
authors.initials: C
authors.lastname: Quereda
authors.forename: Ana
authors.initials: A
authors.lastname: Moreno
authors.forename: Ma Jesús
authors.initials: MJ
authors.lastname: Pérez-Elías
authors.forename: Pilar
authors.initials: P
authors.lastname: Martín-Dávila
authors.forename: Emilio
authors.initials: E
authors.lastname: de Vicente
authors.forename: Rafael
authors.initials: R
authors.lastname: Bárcena
authors.forename: Yolanda
authors.initials: Y
authors.lastname: Quijano
authors.forename: Miguel
authors.initials: M
authors.lastname: García
authors.forename: Javier
authors.initials: J
authors.lastname: Nuño
authors.forename: Adolfo
authors.initials: A
authors.lastname: Martínez
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017093:Liver Failure / Q000150:complications* / Q000601:surgery*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D019966:Substance-Related Disorders / Q000150:complications
chemical_list: D007166:Immunosuppressive Agents; D012367:RNA, Viral